FINWIRES · TerminalLIVE
FINWIRES

$CC

5 stories mentioning CCUpdated just now

Every FINWIRES story that references CC, newest first.

Wire

Chemours to Pay $22.5 Million Penalty, Implement Relief Programs to Resolve 'Forever Chemicals' Environmental Claims

Chemours (CC) and the US Department of Justice said Wednesday that the company has reached a multi-state settlement with the US Environmental Protection Agency to resolve claims related to PFAS discharges and other alleged environmental compliance violations.The DOJ added that the cost of the penalty plus injunctive relief programs is estimated to exceed $450 million. The West Virginia Department of Environmental Protection is also a party to the settlement, they added.The complaint alleges that Chemours facilities in West Virginia, North Carolina, and New Jersey discharged PFAS, which are synthetic "forever chemicals," into the Ohio, Cape Fear, and Delaware rivers. It also alleges that Chemours failed to comply with requirements under the Toxic Substances Control Act at four facilities. These violations allegedly continued for more than a decade, the DOJ said.Under the agreement, Chemours said it agreed to pay a $22.5 million civil penalty to the EPA and WVDEP, including $15 million that had already been accrued. The penalty will be paid in three annual installments in 2026, 2027, and 2028, starting within 30 days after court approval of the settlement, the company said.Shares of Chemours rose about 2.7% in the session.Price: $20.50, Change: $+0.54, Percent Change: +2.71%

$CC
Wire

Chemours Reiterated 2026 Guidance but Investors Wanted Stronger Signal, RBC Says

Chemours (CC) reiterating its 2026 guidance may be viewed as weaker than peers, and investors may have been looking for a stronger signal from management of an H2 boost, RBC Capital Markets said in a note emailed Monday.Chemours secured a long-term chlorine supply contract with Olin (OLN) starting in 2028, aimed at strengthening its competitive position, the firm said. By that time, the PCC plant is expected to come online and deliver solid cost benefits for the company, according to the note.While the company should benefit from the Middle East conflict-driven sulfur cost inflation impacting sulfate-based TiO2 competitors, price has yet to boost earnings, which should start in H2, the brokerage added.RBC kept an outperform rating on Chemours and raised the price target to $29 from $26.Price: $25.31, Change: $+2.27, Percent Change: +9.85%

$CC
Research

Research Alert: CFRA Keeps Sell On Shares Of The Chemours Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price at $12 using a forward P/E of 6.0x our 2027 EPS view of $1.99, a discount to the five-year average on near-term fundamental concerns and lingering litigation issues. We keep our 2026 EPS view at $1.33 and our 2027 EPS at $1.99. We keep our Sell rating on shares of Chemours Company after Q1 earnings release as we think CC faces high risk from a multitude of litigation issues, most notably its involvement in PFAS lawsuits and may be negatively impacted by increased regulation on chemicals. CC posted net sales of $1.381B (+1% Y/Y) with mixed segment performances. Solid performance in the TSS segment (+22% Y/Y) fell short to counterbalance headwinds in the TT segment with sales declining 6% Y/Y and in the APM segment, with sales down 17% Y/Y. The Washington Works plant outage also constrained production in Q1, contributing ~$25M negative impact and highlights operational execution risks across the company's manufacturing footprint, in our view.

$CC
Wire

Chemours Shares Fall After Q1 Earnings Decline

Chemours (CC) shares were down 16% in Wednesday trading after the company reported lower Q1 earnings, while revenue missed analysts' estimates.The company posted Q1 adjusted earnings late Tuesday of $0.05 per diluted share, down from $0.13 a year earlier.Analysts polled by FactSet expected a loss of $0.04.Net sales for the quarter ended March 31 were $1.38 billion, compared with $1.37 billion a year earlier.Analysts polled by FactSet expected $1.40 billion.For Q2, the company expects consolidated net sales to increase in the range of 15% to 20% sequentially, while for 2026, Chemours continues to expect net sales to grow in the range of 3% to 5% over 2025.Analysts expect Q2 sales of $1.66 billion and 2026 sales of $6.03 billion.Price: $23.29, Change: $-4.65, Percent Change: -16.64%

$CC
Research

Research Alert: Cc Posts Mixed Q1, Focus Is On Growth, Profitability, And Debt Reduction

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Chemours posted mixed Q1 results, with sales of $1.381B (+1% Y/Y), $20M below expectations, while adjusted EPS of $0.05 beat by $0.09 but declined from $0.13 prior year. Net loss widened to $29M from $5M due to higher financing costs and increased SG&A expenses. The results reflected significant segment divergence, with record TSS performance (+22% Y/Y to $568M) offsetting TT weakness (-6% Y/Y) and APM disruptions (-17% Y/Y). Management guided Q2 sequential sales growth of 15%-20% and full-year 2026 growth of 3%-5% Y/Y, with adjusted EBITDA of $800M-$900M. We view TSS's performance favorably due to Opteon refrigerant adoption and strong automotive Freon sales, achieving 33% adjusted EBITDA margin. However, we remain concerned about TT's margin compression to 3% from competitive pressures by lower-cost Asian producers and APM's operational challenges from Washington Works plant outage. We believe the deleveraging target to reduce net leverage from 4.9x to below 3.8x by year-end 2026 will be important.

$CC

Track with the FINWIRES app suite

FolioX
FolioX
Track CC in your portfolio
WheelAI
WheelAI
Analyze CC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CC